Heated tobacco products for smoking cessation and reducing smoking prevalence

Abstract

Background Heated tobacco products (HTPs) are designed to heat tobacco to a high enough temperature to release aerosol, without burning it or producing smoke. They differ from e‐cigarettes because they heat tobacco leaf/sheet rather than a liquid. Companies who make HTPs claim they produce fewer harmful chemicals than conventional cigarettes. Some people report stopping smoking cigarettes entirely by switching to using HTPs, so clinicians need to know whether they are effective for this purpose and relatively safe. Also, to regulate HTPs appropriately, policymakers should understand their impact on health and on cigarette smoking prevalence. Objectives To evaluate the effectiveness and safety of HTPs for smoking cessation and the impact of HTPs on smoking prevalence. Search methods We searched the Cochrane Tobacco Addiction Group's Specialised Register, CENTRAL, MEDLINE, and six other databases for relevant records to January 2021, together with reference‐checking and contact with study authors and relevant groups. Selection criteria We included randomised controlled trials (RCTs) in which people who smoked cigarettes were randomised to switch to exclusive HTP use or a control condition. Eligible outcomes were smoking cessation, adverse events, and selected biomarkers. RCTs conducted in clinic or in an ambulatory setting were deemed eligible when assessing safety, including those randomising participants to exclusively use HTPs, smoke cigarettes, or attempt abstinence from all tobacco. Time‐series studies were also eligible for inclusion if they examined the population‐level impact of heated tobacco on smoking prevalence or cigarette sales as an indirect measure. Data collection and analysis We followed standard Cochrane methods for screening and data extraction. Our primary outcome measures were abstinence from smoking at the longest follow‐up point available, adverse events, serious adverse events, and changes in smoking prevalence or cigarette sales. Other outcomes included biomarkers of harm and exposure to toxicants/carcinogens (e.g. NNAL and carboxyhaemoglobin (COHb)). We used a random‐effects Mantel‐Haenszel model to calculate risk ratios (RR) with 95% confidence intervals (CIs) for dichotomous outcomes. For continuous outcomes, we calculated mean differences on the log‐transformed scale (LMD) with 95% CIs. We pooled data across studies using meta‐analysis where possible. Main results We included 13 completed studies, of which 11 were RCTs assessing safety (2666 participants) and two were time‐series studies. We judged eight RCTs to be at unclear risk of bias and three at high risk. All RCTs were funded by tobacco companies. Median length of follow‐up was 13 weeks. No studies reported smoking cessation outcomes. There was insufficient evidence for a difference in risk of adverse events between smokers ...

Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission

“…301 Under standing of exposure to e-cigarette smoke is growing, and it is now clear that vaping is harmful. Due to a lack of legislation and conflicting approaches to e-cigarette use in the medical field, 302 e-cigarettes and vapes can often be used in smoke-free areas and public confusion persists regarding their harmful effects.…”

The role of IQOS risk perceptions on cigarette smoking behaviours: results from a prospective pilot study

“…Current and former smokers reported that their perceptions of reduced harm were important in their decision to use IQOS, with most reporting concurrent IQOS and cigarette use 5. IQOS marketing asserts that switching completely from cigarettes to IQOS is necessary to obtain reduced toxicant exposure 7…”

Changes in Tobacco Use in the Early Phase of Coronavirus Disease 2019 Pandemic in Hong Kong: A Qualitative Study

“… 47 In addition, a Cochrane Review did not find any randomized controlled trials evaluating the effect of HTPs on cigarette smoking cessation, casting doubt on HTPs ability for this purpose. 48 Although the Hong Kong SAR Government has banned the import, manufacture, sale, distribution, and advertisement of alternative smoking products (ECs, HTPs, herbal cigarettes) on April 30, 2022, use of these products remain legal. 49 Smokers need better awareness of the risk of EC and HTP use to themselves and others, and their risk of addiction and relapse to cigarette use.…”